Zoetis Inc (ZTS)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Zoetis Inc is a Healthcare company with a market capitalization of $31.90B, a trailing P/E ratio of 12.5, and a dividend yield of 2.61%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $1.42 | $1.54 | -7.8% |
| Q4 2025 | February 12, 2026 | $1.48 | $1.40 | +5.7% |
| Q3 2025 | November 4, 2025 | $1.70 | $1.62 | +4.9% |
| Q2 2025 | August 5, 2025 | $1.61 | $1.52 | +5.9% |
| Q1 2025 | May 6, 2025 | $1.48 | $1.40 | +5.7% |
| Q4 2024 | February 13, 2025 | $1.40 | $1.36 | +2.9% |
Other Drug Manufacturers - Specialty & Generic Stocks
Frequently Asked Questions
What is Zoetis Inc's market cap?
As of June 29, 2026, Zoetis Inc (ZTS) has a market capitalization of $31.90B.
What is Zoetis Inc's P/E ratio?
Zoetis Inc trades at a trailing price-to-earnings (P/E) ratio of 12.5. Its forward P/E is 11.1.
Does Zoetis Inc pay a dividend?
Yes — Zoetis Inc pays a dividend yielding 2.61%, an annual payout of $2.03 per share.
What sector is ZTS in?
Zoetis Inc is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
What was Zoetis Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Zoetis Inc reported revenue of $9.47B and net income of $2.67B.
Ask your own questions about ZTS
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.